Literature DB >> 12578922

Rasmussen's encephalitis: early characteristics allow diagnosis.

T Granata1, G Gobbi, R Spreafico, F Vigevano, G Capovilla, F Ragona, E Freri, L Chiapparini, P Bernasconi, L Giordano, G Bertani, M Casazza, B Dalla Bernardina, L Fusco.   

Abstract

OBJECTIVE: To identify early manifestations of Rasmussen encephalitis (RE) that can prompt early and reasonably secure diagnosis, allowing medical or surgical therapies at an early stage when they may be more effective in slowing the disease.
METHODS: The authors studied 12 patients with clinical and neuropathologic diagnosis of RE, followed from disease onset, assessing clinical history, imaging, and EEG and focusing on early characteristics. Anti-GluR3 antibody assays were also considered in 11 patients.
RESULTS: By 4 months from first symptoms, all cases had 1) refractory focal seizures with a predominant motor component, 2) slow focal activity on EEG contralateral to the motor manifestations, and 3) focal contralateral white matter hyperintensity with insular cortical atrophy on neuroimaging. Less constant or later findings were epilepsia partialis continua, oligoclonal bands, and serum anti-GluR3 antibodies.
CONCLUSIONS: The association of partial seizures with focal EEG and neuroimaging changes allows a tentative diagnosis of RE 4 to 6 months after first symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578922     DOI: 10.1212/wnl.60.3.422

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  MRI appearance of Rasmussen encephalitis.

Authors:  Ricardo Faingold; Onyema A Onyekwelu
Journal:  Pediatr Radiol       Date:  2009-03-18

Review 2.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

3.  Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?

Authors:  L Chiapparini; T Granata; L Farina; E Ciceri; A Erbetta; F Ragona; E Freri; L Fusco; G Gobbi; G Capovilla; L Tassi; L Giordano; M Viri; B Dalla Bernardina; R Spreafico; M Savoiardo
Journal:  Neuroradiology       Date:  2003-02-12       Impact factor: 2.804

Review 4.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Authors:  Sophia Varadkar; Christian G Bien; Carol A Kruse; Frances E Jensen; Jan Bauer; Carlos A Pardo; Angela Vincent; Gary W Mathern; J Helen Cross
Journal:  Lancet Neurol       Date:  2014-02       Impact factor: 44.182

5.  Evaluation of quality of life and clinical status of children operated on for intractable epilepsy.

Authors:  Dawid Larysz; Patrycja Larysz; Marek Mandera
Journal:  Childs Nerv Syst       Date:  2006-10-13       Impact factor: 1.475

6.  Rasmussen's encephalitis: advances in management and patient outcomes.

Authors:  Caitlin E Hoffman; Ayako Ochi; Orlando Carter Snead; Elysa Widjaja; Cynthia Hawkins; Martin Tisdal; James T Rutka
Journal:  Childs Nerv Syst       Date:  2016-01-16       Impact factor: 1.475

7.  Difficulties in differentiation of Parry-Romberg syndrome, unilateral facial sclerodermia, and Rasmussen syndrome.

Authors:  Justyna Paprocka; Ewa Jamroz; Dariusz Adamek; Elzbieta Marszal; Marek Mandera
Journal:  Childs Nerv Syst       Date:  2005-10-25       Impact factor: 1.475

Review 8.  Eponym : Rasmussen syndrome.

Authors:  Mario Mastrangelo; Rosanna Mariani; Alessandra Menichella
Journal:  Eur J Pediatr       Date:  2010-02-23       Impact factor: 3.183

Review 9.  Finding on brain MRI mimicking focal cortical dysplasia in early Rasmussen's encephalitis: a case report and review.

Authors:  Kuo-Liang Chiang; Tai-Tong Wong; Shan-Young Kwan; Ting-Rong Hsu; Chung-Hao Wang; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2009-06-11       Impact factor: 1.475

10.  Structural abnormalities in patients with insular/peri-insular epilepsy: spectrum, frequency, and pharmacoresistance.

Authors:  M-C Chevrier; C Bard; F Guilbert; D K Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.